Close Menu

NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has agreed to acquire ACEA Biosciences for $250 million in cash.

Privately held ACEA, which is based in San Diego, has most recently developed a line of xCELLigence impedance-based, label-free, real-time cell analysis instruments that are used in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. The company also sells a line of NovoCyte and NovoCyte Quanteon high-performance benchtop flow cytometry systems.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.